Big Molecule Watch
May 11, 2021

Amgen Canada Launches Adalimumab Biosimilar

On May 4, 2021, Amgen Canada announced the launch of their adalimumab biosimilar AMGEVITA (reference drug HUMIRA) for the treatment of 11 chronic inflammatory conditions.  AMGEVITA is available as a prefilled syringe and a prefilled pen (SureClick® autoinjector) with a range of pack sizes to support dosing according to the approved dosage recommendations in each indication.  AMGEVITA is also provided in a citrate-free formulation.

Suna Avcil, executive medical director of Amgen Canada, stated “We are pleased that AMGEVITA is now available in Canada, offering patients and physicians a treatment option and flexibility of choice in therapies they may not otherwise have.”

The post Amgen Canada Launches Adalimumab Biosimilar appeared first on Big Molecule Watch.